Protagonist Therapeutics, Inc. (PTGX)

82.04 -2.14 (-2.54%) USD  |  NASDAQ  |  Jan 06, 15:46
More

Protagonist Therapeutics Research and Development Expense (Annual): 138.13M for Dec. 31, 2024

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for PTGX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Johnson & Johnson 17.26B
ADMA Biologics, Inc. 1.813M
Bristol Myers Squibb Co. 9.782B
MannKind Corp. 45.89M
Regeneron Pharmaceuticals, Inc. 4.624B